Blar i forfatter "Bendz, Bjørn"

Viser treff 1-11 av 11

    • BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study 

      Munkhaugen, John; Ruddox, Vidar; Halvorsen, Sigrun; Dammen, Toril; Fagerland, Morten; Hernæs, Kjersti Helene; Vethe, Nils Tore; Prescott, Eva; Jensen, Svend Eggert; Rødevand, Olaf; Jortveit, Jarle; Bendz, Bjørn; Schirmer, Henrik; Kõber, Lars; Botker, Hans Erik; Larsen, Alf Inge; Vikenes, Kjell; Steigen, Terje; Wiseth, Rune; Pedersen, Terje Rolf; Edvardsen, Thor; Otterstad, Jan Erik; Atar, Dan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-25)
      <p><i>Background - </i>Current guidelines on the use of β-blockers in post–acute myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF) are based on studies before the implementation of modern reperfusion and secondary prevention therapies. It remains unknown whether β-blockers will reduce mortality and recurrent MI in contemporary revascularized post-MI patients ...

    • Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab 

      Woxholt, Sindre; Ueland, Thor; Aukrust, Pål; Anstensrud, Anne Kristine; Broch, Kaspar; Tøllefsen, Ingvild Maria; Ryan, Liv; Bendz, Bjørn; Hopp, Einar; Kløw, Nils-Einar; Seljeflot, Ingebjørg; Halvorsen, Bente; Dahl, Tuva Børresdatter; Huse, Camilla; Andersen, Geir Øystein; Gullestad, Lars; Wiseth, Rune; Amundsen, Brage H.; Damås, Jan Kristian; Kleveland, Ola (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-08-17)
      Background - Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), troponin T, MSI and infarct size.<p> <p>Methods - STEMI patients were randomised to receive a single ...

    • IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction 

      Orrem, Hilde Lang; Nilsson, Per; Pischke, Søren Erik; Kleveland, Ola; Yndestad, Arne; Ekholt, Karin; Damås, Jan Kristian; Espevik, Terje; Bendz, Bjørn; Halvorsen, Bente; Gregersen, Ida; Wiseth, Rune; Andersen, Geir Øystein; Ueland, Thor; Gullestad, Lars; Aukrust, Pål; Barratt-Due, Andreas; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-12)
      <p><i>Background</i>: Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated the effect of the IL-6 receptor (IL-6R)-antagonist tocilizumab on the expression of the ...

    • Incidence and risk factors for major bleeding among patients undergoing percutaneous coronary intervention: Findings from the Norwegian Coronary Stent Trial (NORSTENT) 

      Samuelsen, Per-Jostein; Eggen, Anne Elise; Steigen, Terje; Wilsgaard, Tom; Kristensen, Andreas; Skogsholm, Anne; Holme, Elizabeth; van den Heuvel, Christian; Nordrehaug, Jan Erik; Bendz, Bjørn; Nilsen, Dennis W.T.; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-03-04)
      Introduction - Bleeding is a concern after percutaneous coronary intervention (PCI) and subsequent dual antiplatelet therapy (DAPT). We herein report the incidence and risk factors for major bleeding in the Norwegian Coronary Stent Trial (NORSTENT). <p> <p>Materials and methods - NORSTENT was a randomized, double blind, pragmatic trial among patients with acute coronary syndrome or stable coronary ...

    • Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial 

      Huse, Camilla; Anstensrud, Anne Kristine; Michelsen, Annika Elisabet; Ueland, Thor; Broch, Kaspar; Woxholt, Sindre; Yang, Kuan; Sharma, Kapil Kishore; Tøllefsen, Ingvild Maria; Bendz, Bjørn; Amundsen, Brage H.; Damås, Jan Kristian; Berg, Erlend Sturle; Bjørkelund, Elisabeth; Quiles-Jiménez, Ana M T; Bjerkeli, Vigdis; Bendz, Christina; Kleveland, Ola; Stensæth, Knut Haakon; Opdahl, Anders; Kløw, Nils-Einar; Andersen, Geir Øystein; Wiseth, Rune; Halvorsen, Bente; Gullestad, Lars; Seljeflot, Ingebjørg; Aukrust, Pål; Osnes, Liv T. N.; Dahl, Tuva Børresdatter (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-04-30)
      Background We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the mechanisms for this effect are not clear.<p> <p>Methods In this exploratory sub-study of the ASSAIL-MI trial, we examined leukocyte differential counts and their relation to myocardial salvage and peak troponin T (TnT) in STEMI ...

    • Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction 

      Kleveland, Ola; Ueland, Thor; Kunszt, Gabor; Bratlie, Marte; Yndestad, Arne; Broch, Kaspar; Holte, Espen; Ryan, Liv; Amundsen, Brage H.; Bendz, Bjørn; Aakhus, Svend; Espevik, Terje; Halvorsen, Bente; Mollnes, Tom Eirik; Wiseth, Rune; Gullestad, Lars; Aukrust, Pål; Damås, Jan Kristian (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-06-29)
      <p><i>Aim</i>: To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network in patients with acute non-ST-elevation myocardial infarction (NSTEMI).</p> <p><i>Methods</i>: 117 patients with acute NSTEMI were randomised to an intravenous infusion of 280 mg tocilizumab or placebo prior to coronary angiography. Blood samples were obtained at baseline, at 6 consecutive ...

    • Legumain is upregulated in acute cardiovascular events and associated with improved outcome – potentially related to anti-inflammatory effects on macrophages 

      Lunde, Ngoc Dieu Nguyen; Gregersen, Ida; Ueland, Thor; Shetelig, Christian; Holm, Sverre; Kong, Xiang Yi; Michelsen, Annika; Otterdal, Kari; Yndestad, Arne; Broch, Kaspar; Gullestad, Lars; Nyman, Tuula Anneli; Bendz, Bjørn; Eritsland, Jan; Hoffmann, Pavel; Skagen, Karolina Ryeng; Gonçalves, Isabel; Nilsson, Jan; Grenegård, Magnus; Poreba, Marcin; Drag, Marcin; Seljeflot, Ingebjørg; Sporsheim, Bjørnar; Espevik, Terje; Skjelland, Mona; Johansen, Harald Thidemann; Solberg, Rigmor; Aukrust, Pål; Björbacka, Harry; Andersen, Geir Øystein; Halvorsen, Bente (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-12-14)
      <i>Background and aims</i> - We have previously found increased levels of the cysteine protease legumain in plasma and plaques from patients with carotid atherosclerosis. This study further investigated legumain during acute cardiovascular events.<p><p> <i>Methods</i> - Circulating levels of legumain from patients and legumain released from platelets were assessed by enzyme-linked-immunosorbent ...

    • Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction 

      Broch, Kaspar; Anstensrud, Anne Kristine; Woxholt, Sindre; Sharma, Kapil Kishore; Tøllefsen, Ingvild Maria; Bendz, Bjørn; Aakhus, Svend; Ueland, Thor; Amundsen, Brage H.; Damås, Jan Kristian; Berg, Erlend; Bjørkelund, Elisabeth; Bendz, Christina; Hopp, Einar; Kleveland, Ola; Stensæth, Knut Haakon; Opdahl, Anders; Kløw, Nils-Einar; Seljeflot, Ingebjørg; Andersen, Geir Øystein; Wiseth, Rune; Aukrust, Pål; Gullestad, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-04-12)
      <p><i>Background - </i>Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, as much as 50% of the loss of viable myocardium may be attributed to the reperfusion injury and the associated inflammatory response. <p><i>Objectives - </i>This study sought ...

    • Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI) 

      Anstensrud, Anne Kristine; Voxholt, Sindre; Sharma, Kapil; Broch, Kaspar; Bendz, Bjørn; Aakhus, Svend; Ueland, Thor; Amundsen, Brage H.; Damås, Jan Kristian; Hopp, Einar; Kleveland, Ola; Stensæth, Knut Haakon; Opdahl, Anders; Kløw, Nils-Einar; Seljeflot, Ingebjørg; Andersen, Geir Øystein; Wiseth, Rune; Aukrust, Pål; Gullestad, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-10-15)
      <i>Introduction</i>: Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation MI (NSTEMI). Experimental studies suggest that IL-6 inhibition can limit infarct size through ...

    • Reduced inflammatory response by transcatheter, as compared to surgical aortic valve replacement 

      Hauge, Karoline Kråkmo; Dahle, Gry; Bendz, Bjørn; Halvorsen, Per Steinar; Abdelnoor, Michael; Mollnes, Tom Eirik; Fosse, Erik (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-12-12)
      <i>Objectives</i>. The inflammatory response to on-pump cardiac surgery is well known. Systemic inflammatory response syndrome after transcatheter valve implantation (TAVI) has been reported. The objective of this study was to study the inflammatory response during TAVI, and compare with the response during surgical aortic valve replacement. <i>Methods</i>. Eighteen patients undergoing transcatheter ...

    • Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction 

      Helseth, Ragnhild; Kleveland, Ola; Ueland, Thor; Wiseth, Rune; Damås, Jan Kristian; Broch, Kaspar; Michelsen, Annika Elisabet; Bendz, Bjørn; Gullestad, Lars; Aukrust, Pål; Seljeflot, Ingebjørg (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-10)
      Objective: Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to formation of neutrophil extracellular traps (NETs), carrying inflammatory and thrombotic properties.<p> <p>Methods - In a placebo-controlled ...